Edesa Biotech is trading at $6.00 (+5.03%) in the August 19, 2026 pre-market session, with no clear company-specific catalyst identified.
- Recent fiscal third-quarter results reported a $5.4 million net loss, while recruitment for the Phase 2 EB06 vitiligo study was expected to begin; that news was released August 13, not overnight.
- After-hours coverage also described the move as occurring without a clearly identified catalyst.
- Broader indices were mixed, so market-wide sentiment does not clearly explain the move.